Effect of nabiximols oromucosal spray (Sativex®) on symptoms associated with multiple sclerosis-related spasticity: a case series
Spasticity and its related symptoms of spasms, pain, sleep disturbance and bladder dysfunction are common in persons with multiple sclerosis (MS) and may be interconnected through a common pathophysiology and/or may trigger and worsen each other. Tetrahydrocannabinol–cannabidiol (nabiximols) oromuco...
Main Authors: | Niklas Garde, Markus Heibel |
---|---|
Format: | Article |
Language: | English |
Published: |
BioExcel Publishing Ltd
2024-02-01
|
Series: | Drugs in Context |
Subjects: | |
Online Access: | https://www.drugsincontext.com/effect-of-nabiximols-oromucosal-spray-sativex-on-symptoms-associated-with-multiple-sclerosis-related-spasticity-a-case-series/ |
Similar Items
-
Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience
by: Marie D’hooghe, et al.
Published: (2021-06-01) -
A Review of Scientific Evidence for THC:CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain
by: Überall MA
Published: (2020-02-01) -
Variability of Multiple Sclerosis Spasticity Symptoms in Response to THC:CBD Oromucosal Spray: Tracking Cases through Clinical Scales and Video Recordings
by: Peter Flachenecker, et al.
Published: (2018-07-01) -
NAbiximols Clinical Translation To the treatment of Pain and Agitation In Severe Dementia (NACTOPAISD): Clinical trial protocol
by: D. Scuteri, et al.
Published: (2022-09-01) -
Non‐interventional, prospective, observational study on spasticity‐associated symptom control with nabiximols as add‐on therapy in patients with multiple sclerosis spasticity in Austria
by: Michael Guger, et al.
Published: (2023-04-01)